Navigation Links
Ansell Launches Worlds's First Antimicrobial Surgical Glove
Date:5/4/2010

MELBOURNE, May 4, 2010 /PRNewswire/ -- Ansell today announced the launch of their new GAMMEX(R) Powder-Free glove with AMT Antimicrobial Technology, at the Annual Congress of the Royal Australasian College of Surgeons in Perth, Australia.

It is the first surgical glove which incorporates a proprietary antimicrobial coating to provide an additional level of protection to surgical staff against viruses and bacteria, in the event of a breach during surgery.

The last decade has witnessed a rapid expansion of the medical gloves market globally. Major drivers for this growth are improving healthcare systems around the world and the increasing awareness by healthcare workers that gloves offer an effective protective barrier against contamination from bacteria and viruses. Ansell's new AMT Antimicrobial Technology reduces surgical staff risks of exposure to blood-borne pathogens through a higher level of protection.

Extensive in vitro laboratory testing showed that the antimicrobial coating killed >99 per cent of Hepatitis C1 and 99 percent of HIV-1 (strain Mn) within 60 seconds of exposure through a simulated glove breach.

GAMMEX(R) Powder-Free glove with AMT Antimicrobial Technology also kills between 99.7% to >99.999% of 8 common healthcare infectious bacteria, comprising gram-positive, gram-negative, and drug-resistant bacteria (e.g. MRSA, VRE) within 60 seconds from exposure.

"Ansell's proprietary AMT Antimicrobial surgical glove technology is the result of intensive and collaborative research, and demonstrates the Company's ability for industry leading innovation and new product development", says Magnus Nicolin, CEO of Ansell Ltd.

"It also underscores Ansell's commitment to continuously invest in seeking optimal solutions to better protect healthcare professionals in a world with an increasing number of high risk pathogens", he continues.

GAMMEX(R) Powder-Free glove with AMT Antimicrobial Technology features a unique and proprietary inner coating, containing skin friendly agents and chlorhexidine gluconate (CHG), an effective antimicrobial agent commonly found in products such as antiseptics and mouthwash.

Ansell's AMT Antimicrobial Technology is a world first and is now being launched in Australia. It will be progressively rolled out in all Ansell markets

1, Tested versus Bovine Viral Diarrhea Virus (BVDV), a common surrogate for Hepatitis C.

About Ansell

Ansell is a world leader in providing superior health and safety protection solutions that enhance human well being. With operations in the Americas, Europe and Asia Pacific, Ansell employs more than 10,000 people worldwide and holds leading market positions in industrial and medical gloves. Ansell is also a leading player in the household gloves and condom market segment globally. Information on Ansell and its products can be found at http://www.ansell.com.


'/>"/>
SOURCE Ansell Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Managing Risk Through Quality: Ansell Healthcares Innovative Gammex(R) Glove Range on Display at Arab Health 2009
2. Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide
3. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
4. Novozymes Launches Enzyme to Reduce Acrylamide in Food
5. Enova Medical Launches Exos Corporation
6. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
7. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
8. ThirdBiotech Networking Group Launches
9. BioReliance Launches Next-Generation Genotoxicity Screening Service
10. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
11. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/9/2016)... TURKU, Finland , June 9, 2016 ... French National Police deploy Teleste,s video security solution to ensure ... France during the major tournament ... and data communications systems and services, announced today that its ... Police Prefecture to back up public safety across ...
Breaking Biology News(10 mins):